Gujarat Themis Biosyn Ltd.
Fundamentals
- Market cap
- ₹4,246 cr
- P/E
- 90.95×
- ROE
- 19.64%
- Debt / equity
- 0.12
- Div yield
- 0.17%
- 52-week range
- 225.75 — 479.45
Gujarat Themis Biosyn Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 6 notes on Gujarat Themis Biosyn Ltd.
July 2026
- 17 Jul 26 · 5:18 PM IST Brief Brief · Credit · Small cap
Gujarat Themis placed on rating watch; acquisitions cost 10x net worth
CARE flagged that Gujarat Themis's planned acquisitions are ten times its tangible net worth and funding is uncertain. The company protests, but the rating action signals a possible downgrade.
- 02 Jul 26 · 8:19 AM IST Lead Lead · Small cap
Gujarat Themis promoter stake is now tied to third-party debt
CTL Trusteeship discloses indirect encumbrance of the entire 47.02% promoter holding to secure debentures of OSS Software Solutions Labs, a previously undisclosed development that exposes the controlling block to enforcement risk.
June 2026
- 06 Jun 26 · 7:19 PM IST Alert Alert · Small cap
Gujarat Themis will dilute a fifth of itself for a ¥21.5bn Japan deal
A ₹1,000 cr QIP and a separate preferential issue will fund the MicroBiopharm Japan acquisition.
- 03 Jun 26 · 6:14 PM IST Brief Brief · Small cap
Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal
The board will meet June 6 to decide on a QIP, preferential allotment, or other equity route. The raise will fund last month's ¥21.5 bn acquisition of MicroBiopharm Japan.
May 2026
- 25 May 26 · 3:09 PM IST Brief Brief · Small cap
Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
FY26 results are routine. The board's separate approval for a preferential equity issue to non-promoters is not.
- 22 May 26 · 8:39 PM IST Alert Alert · M&A · Small cap
Gujarat Themis Biosyn bets ₹1,300 cr to buy Japan's MicroBiopharm
The deal is valued at 33% of the company's market cap and aims to shift its focus from intermediates to high-tech CDMO services.